Peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTA-TATE

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Neuroendocrine tumors (NETs) are a diverse group of neoplasms.
• Somatostatin receptors play a crucial role in NET biology and targeted therapy.
• Radiolabeled peptide receptor therapy (PRRT) has emerged as a significant treatment modality for NETs.

Purpose of the Study:

• To provide a comprehensive overview of PRRT for neuroendocrine tumors.
• To elucidate patient selection criteria, administration protocols, and response evaluation for PRRT.
• To discuss the role of functional imaging and the future directions in PRRT.

Main Methods:

• Review of the biology of neuroendocrine tumors and somatostatin receptors.
• Analysis of patient selection criteria and inclusion guidelines for PRRT.
• Discussion of PRRT administration, follow-up, and response assessment.
• Exploration of functional imaging in teragnosis and personalized treatment.

Main Results:

• PRRT is a well-tolerated and safe therapeutic option for NETs.
• Adverse effects of PRRT are generally mild and self-limited.
• Functional imaging is essential for understanding tumor biology and guiding individualized treatment.

Conclusions:

• PRRT is an effective and safe treatment for neuroendocrine tumors when appropriately sequenced.
• Optimal patient selection and multidisciplinary evaluation are crucial for successful PRRT.
• Ongoing research aims to enhance PRRT efficacy through new agents, radionuclides, and combination therapies.